Vanguard Group Inc boosted its position in shares of Enanta Pharmaceuticals Inc (NASDAQ:ENTA) by 30.1% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,426,791 shares of the biotechnology company’s stock after buying an additional 330,374 shares during the period. Vanguard Group Inc owned approximately 7.35% of Enanta Pharmaceuticals worth $121,934,000 at the end of the most recent quarter.
A number of other institutional investors have also recently made changes to their positions in ENTA. Vanguard Group Inc. grew its stake in Enanta Pharmaceuticals by 30.1% during the third quarter. Vanguard Group Inc. now owns 1,426,791 shares of the biotechnology company’s stock worth $121,934,000 after buying an additional 330,374 shares in the last quarter. Matarin Capital Management LLC acquired a new stake in shares of Enanta Pharmaceuticals in the 3rd quarter valued at approximately $17,964,000. BlackRock Inc. boosted its stake in shares of Enanta Pharmaceuticals by 6.5% in the 3rd quarter. BlackRock Inc. now owns 2,590,166 shares of the biotechnology company’s stock valued at $221,354,000 after purchasing an additional 157,166 shares in the last quarter. First Manhattan Co. boosted its stake in shares of Enanta Pharmaceuticals by 22.7% in the 3rd quarter. First Manhattan Co. now owns 698,434 shares of the biotechnology company’s stock valued at $59,688,000 after purchasing an additional 129,026 shares in the last quarter. Finally, Teachers Advisors LLC boosted its stake in shares of Enanta Pharmaceuticals by 249.0% in the 3rd quarter. Teachers Advisors LLC now owns 107,124 shares of the biotechnology company’s stock valued at $9,155,000 after purchasing an additional 76,426 shares in the last quarter. Hedge funds and other institutional investors own 84.83% of the company’s stock.
A number of equities research analysts have recently weighed in on ENTA shares. Zacks Investment Research upgraded shares of Enanta Pharmaceuticals from a “hold” rating to a “buy” rating and set a $87.00 price target on the stock in a research note on Tuesday, October 9th. ValuEngine downgraded shares of Enanta Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 8th. BidaskClub upgraded shares of Enanta Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, November 20th. TheStreet downgraded shares of Enanta Pharmaceuticals from a “b-” rating to a “c+” rating in a research note on Monday, November 26th. Finally, Oppenheimer set a $100.00 price target on shares of Enanta Pharmaceuticals and gave the company a “hold” rating in a research note on Tuesday, November 27th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and four have given a buy rating to the stock. Enanta Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $100.00.
Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings data on Monday, November 26th. The biotechnology company reported $1.30 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.24 by $0.06. The business had revenue of $67.20 million during the quarter, compared to analyst estimates of $69.03 million. Enanta Pharmaceuticals had a net margin of 34.82% and a return on equity of 21.56%. The firm’s quarterly revenue was down 11.5% on a year-over-year basis. During the same quarter last year, the business earned $1.86 EPS. Sell-side analysts anticipate that Enanta Pharmaceuticals Inc will post 1.7 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: “Vanguard Group Inc Has $121.93 Million Holdings in Enanta Pharmaceuticals Inc (ENTA)” was first reported by WKRB News and is owned by of WKRB News. If you are reading this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The original version of this piece of content can be accessed at https://www.wkrb13.com/2019/01/14/vanguard-group-inc-has-121-93-million-holdings-in-enanta-pharmaceuticals-inc-enta.html.
Enanta Pharmaceuticals Profile
Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus.
Read More: What is Compound Interest?
Want to see what other hedge funds are holding ENTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enanta Pharmaceuticals Inc (NASDAQ:ENTA).
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.